Hacker News Top Stories with Summaries (November 21, 2023)
<style>
p {
font-size: 16px;
line-height: 1.6;
margin: 0;
padding: 10px;
}
h1 {
font-size: 24px;
font-weight: bold;
margin-top: 10px;
margin-bottom: 20px;
}
h2 {
font-size: 18px;
font-weight: bold;
margin-top: 10px;
margin-bottom: 5px;
}
ul {
padding-left: 20px;
}
li {
margin-bottom: 10px;
}
.summary {
margin-left: 20px;
margin-bottom: 20px;
}
</style>
<h1> Hacker News Top Stories</h1>
<p>Here are the top stories from Hacker News with summaries for November 21, 2023 :</p>
<div style="margin-bottom: 20px;">
<table cellpadding="0" cellspacing="0" border="0">
<tr>
<td style="padding-right: 10px;">
<div style="width: 200px; height: 100px; border-radius: 10px; overflow: hidden; background-image: url('https://i.insider.com/655bd70b22cf74a5739a7df7?width=1200&format=jpeg'); background-size: cover; background-position: center;">
OpenAI's employees were given two explanations for why Sam Altman was fired
Summary: OpenAI employees were given two explanations for CEO Sam Altman's ouster, but remain unconvinced and furious. Most of the company is now prepared to quit. An open letter signed by over 90% of employees demands the resignation of the remaining board members, new appointments, and Altman's return.
<div style="margin-bottom: 20px;">
<table cellpadding="0" cellspacing="0" border="0">
<tr>
<td style="padding-right: 10px;">
<div style="width: 200px; height: 100px; border-radius: 10px; overflow: hidden; background-image: url('https://media.cnn.com/api/v1/images/stellar/prod/230928132232-01-sickle-cell-blood-transfusion-file.jpg?c=16x9&q=w_800,c_fill'); background-size: cover; background-position: center;">
FDA considers first CRISPR gene editing treatment that may cure sickle cell
Summary: The FDA is considering a CRISPR gene editing treatment called exa-cel, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, that could potentially cure sickle cell disease. If approved, it would be the first FDA-approved treatment using CRISPR technology. The therapy involves altering the patient's own stem cells with CRISPR to fix genetic issues causing sickle cell disease, and then infusing the modified stem cells back into the patient.